The link between APOC3, hypertriglyceridemia and cardiovascular risk has been confirmed in extensive animal and humans studies, and abundant data support that the reduction in circulating levels of APOC3 levels (e.g., using anti-sense oligonucleotide targeting the hepatic mRNA of Apoc3 [40]) may represent a valid target for hypotriglyceridemic therapy [39,41]. The gene discussed is APOC3; the disease is hypertriglyceridemia.